SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
7 references·2 citing·42 second hop
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey (2021)Access to cancer medicines deemed essenti…Enhancing global access to cancer medicines (2020)Enhancing global access to ca…Measuring financial protection against catastrophic health expenditures: methodological challenges for global monitoring (2018)Measuring financial protectio…Biosimilar Cost Savings in the United States: Initial Experience and Future Potential (2017)Biosimilar Cost Savings in th…Essential medicines for universal health coverage (2016)Essential medicines for unive…Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2014)Global, regional, and nationa…Catastrophic health payments and health insurance: Some counterintuitive evidence from one low-income country (2007)Catastrophic health payments …Optimal payment systems for health services (1990)Optimal payment systems for h…Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward (2022)Cancer medicines on the WHO M…Barriers in access to oncology drugs — a global crisis (2022)Barriers in access to oncolog…The Bargaining Problem (1950)Perfect Equilibrium in a Bargaining Model (1982)Incentives and provider payment methods (1995)Moral Hazard and Risk Spreading in Partnerships (1995)UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE (2003)How payment systems affect physicians’ provision behaviour—An experimental investigation (2011)The analysis of household surveys (1997)Catastrophe and impoverishment in paying for health care: with applications to Vietnam 1993–1998 (2003)Household catastrophic health expenditure: a multicountry analysis (2003)Measuring financial protection in health (2008)The financial protection effect of Ghana National Health Insurance Scheme: evidence from a study in two rural districts (2011)The Impact of Universal Coverage Schemes in the Developing World : A Review of the Existing Evidence (2013)XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c (1825)Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012)The State of US Health, 1990-2010 (2013)Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016)Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017)Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 (2024)The price of innovation: new estimates of drug development costs (2003)Cochrane Handbook for Systematic Reviews of Interventions (2008)Cochrane Handbook for Systematic Reviews of Interventions (2010)Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending (2017)The path to longer and healthier lives for all Africans by 2030: the Lancet Commission on the future of health in sub-Saharan Africa (2017)Health systems development in Thailand: a solid platform for successful implementation of universal health coverage (2018)Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018)The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment (2018)THE VALUE OF EVERYTHING: MAKING AND TAKING IN THE GLOBAL ECONOMY (2019)An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access (2021)Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks (2017)A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics (2018)Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities (2022)25 years of the WHO essential medicines lists: progress and challenges (2003)The High Cost of Cancer Drugs and What We Can Do About It (2012)Health disparities in neurology (2025)The financial toxicity of cancer: unveiling global burden and risk factors – a systematic review and meta-analysis (2025)Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future (2020)Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications (2021)Overview of the main methods used for estimating catastrophic health expenditure (2023)Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition (2018)Innovation and competition in advanced therapy medicinal products (2019)Why Are Biosimilars Not Living up to Their Promise in the US? (2019)
this work references cited by second hop

References

  • 2014Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 20137,435 cited
  • 2016Essential medicines for universal health coverage661 cited
  • 1990Optimal payment systems for health services321 cited
  • 2017Biosimilar Cost Savings in the United States: Initial Experience and Future Potential208 cited
  • 2020Enhancing global access to cancer medicines205 cited
  • 2007Catastrophic health payments and health insurance: Some counterintuitive evidence from one low-income country178 cited
  • 2018Measuring financial protection against catastrophic health expenditures: methodological challenges for global monitoring98 cited

Cited by

  • 2022Barriers in access to oncology drugs — a global crisis139 cited
  • 2022Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward76 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work